Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats

Molecular Psychiatry

Volumn 20, Issue 8, 2015, Pages 951-958

  Ingallinesi, M ^a   Le Bouil, L ^a   Faucon Biguet, N ^a   Do Thi, A ^a   Mannoury La Cour, C ^b   Millan, M J ^b   Ravassard, P ^a   Mallet, J ^a,c   Meloni, R ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 88; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA; PHENCYCLIDINE; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT; GPR88 PROTEIN, RAT; PHOSPHOPROTEIN DARPP 32; PPP1R1B PROTEIN, RAT;

ADULT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIMARY TISSUE CULTURE; PRIORITY JOURNAL; PUP (RODENT); RAT; SCHIZOPHRENIA; ANIMAL; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MOTOR ACTIVITY; PERCEPTIVE DISCRIMINATION; PHYSIOLOGY; RANDOMIZATION; SOCIAL BEHAVIOR; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; MALE; MICRORNAS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PHENCYCLIDINE; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

EID: 84937794967     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.92     Document Type: Article

References (69)

1. Mizushima K, Miyamoto Y, Tsukahara F, Hirai M, Sakaki Y, Ito T. A novel G-proteincoupled receptor gene expressed in striatum. Genomics 2000; 69: 314-321.
2. Massart R, Guilloux J-P, Mignon V, Pierre S, Jorge D. Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. Eur J Neurosci 2009; 30: 397-414.
3. Van Waes V, Tseng KY, Steiner H. GPR88: a putative signaling molecule predominantly expressed in the striatum: cellular localization and developmental regulation. Basal Ganglia 2011; 1: 83-89.
4. Lobo MK, Xiao-Hong L. Molecular profiling of striatonigral and striatopallidal medium spiny neurons: past, present, and future. Int Rev Neurobiol 2009; 89: 1-35.
5. Sesack SR, Grace AA. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 2010; 35: 27-47.
6. Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 2007; 21: 440-452.
7. Logue SF, Grauer SM, Paulsen J, Graf R, Taylor N, Sung MA, et al. The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders? Mol Cell Neurosci 2009; 42: 438-447.
8. Quintana A, Sanz E, Wang W, Storey GP, Guler AD, Wanat MJ, et al. Lack of GPR88 enhances medium spiny neuron activity and alters motor-and cue-dependent behaviors. Nat Neurosci 2012; 15: 1547-1555.
9. Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry 2012; 17: 887-905.
10. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009; 35: 549-562.
11. Mouri A, Noda Y, Enomoto T, Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 2007; 51: 173-184.
12. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 2001; 107: 535-550.
13. Chang T-C, Mendell JT. microRNAs in vertebrate physiology and human disease. Annu Rev Genom Hum Genet 2007; 8: 215-239.
14. Martin SE, Caplen NJ. Applications of RNA interference in mammalian systems. Annu Rev Genom Hum Genet 2007; 8: 81-108.
15. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20: 515-524.
16. Liu Z, Yan SF, Walker J, Zwingman T, Jiang T, Li J, et al. Study of gene function based on spatial co-expression in a high-resolution mouse brain atlas. BMC Syst Biol 2007; 1: 19.
17. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNAbased system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 2005; 102: 13212-13217.
18. Grace AA. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Rev 2000; 31: 330-341.
19. French SJ, Totterdell S. Hippocampal and prefrontal cortical inputs monosynaptically converge with individual projection neurons of the nucleus accumbens. J Comp Neurol 2002; 446: 151-165.
20. Groenewegen HJ, Trimble M. The ventral striatum as an interface between the limbic and motor systems. CNS Spectr 2007; 12: 887-892.
21. Boctor SY, Ferguson SA. Altered adult locomotor activity in rats from phencyclidine treatment on postnatal days 7, 9 and 11, but not repeated ketamine treatment on postnatal day 7. NeuroToxicol 2010; 31: 42-54.
22. Clifton N, Morisot N, Girardon S, Millan M, Loiseau F. Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology 2013; 225: 579-594.
23. Kabbani N, Levenson R. A proteomic approach to receptor signaling: molecular mechanisms and therapeutic implications derived from discovery of the dopamine D2 receptor signalplex. Eur J Pharmacol 2007; 572: 83-93.
24. Svenningsson P, Nishi A, Fisone G, Girault J-A, Nairn AC, Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 2004; 44: 269-296.
25. Castaing M, Guerci A, Mallet J, Czernichow P, Ravassard P, Scharfmann R. Efficient restricted gene expression in beta cells by lentivirus-mediated gene transfer into pancreatic stem/progenitor cells. Diabetologia 2005; 48: 709-719.
26. Zennou V, Serguera C, Sarkis C, Colin P, Perret E, Mallet J, et al. The HIV-1 DNA flap stimulates HI1V vector-mediated cell transduction in the brain. Nat Biotechnol 2001; 19: 446-450.
27. Santamaria J, Khalfallah O, Sauty C, Brunet I, Sibieude M, Mallet J, et al. Silencing of choline acetyltransferase expression by lentivirus-mediated RNA interference in cultured cells and in the adult rodent brain. J Neurosci Res 2009; 87: 532-544.
28. Paxinos, G Watson, CR. The Rat Brain in Stereotaxic Coordinates, 6th edn. New York, NY, USA: Academic Press, 2007.
29. Terranova JP, Chabot C, Barnouin MC, Perrault G, Depoortere R, Griebel G, et al. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology (Berl) 2005; 181: 134-144.
30. Watson DJ, Loiseau F, Ingallinesi M, Millan MJ, Marsden CA, Fone KC. Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 2012; 37: 770-786.
31. Kiefer H, Chatail-Hermitte F, Ravassard P, Bayard E, Brunet I, Mallet J. ZENON a novel POZ Kruppel-like DNA binding protein associated with differentiation and/or survival of late postmitotic neurons. Mol Cell Biol 2005; 25: 1713-1729.
32. Agulhon C, Rostaing P, Ravassard P, Sagne C, Triller A, Giros B. Lysosomal amino acid transporter LYAAT-1 in the rat central nervous system: an in situ hybridization and immunohistochemical study. J Comp Neurol 2003; 462: 71-89.
33. Anastasio NC, Johnson KM. Atypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups. Pharmacol Biochem Behav 2008; 90: 569-577.
34. Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005; 30: 1963-1985.
35. Braff DL. Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 1993; 19: 233-259.
36. Millan MJ, Bales KL. Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative. Neurosci Biobehav Rev 2013; 37: 2166-2180.
37. Ferré S, Quiroz C, Woods A, Cunha R, Popoli P, Ciruela F, et al. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 2008; 14: 1468-1474.
38. Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lancą AJ, et al. Dopamine D1 and D2 receptor co-activation generates a novel phospholipase c-mediated calcium signal. J Biol Chem 2004; 279: 35671-35678.
39. Maggio R, Millan MJ. Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol 2010; 10: 100-107.
40. Nishi A, Snyder GL, Fienberg AA, Fisone G, Aperia A, Nairn AC, et al. Requirement for DARPP-32 in mediating effect of dopamine D2 receptor activation. Eur J Neurosci 1999; 11: 2589-2592.
41. Jeanneteau F, Guillin O, Diaz J, Griffon N, Sokoloff P. GIPC recruits GAIP (RGS19) to attenuate dopamine D2 receptor signaling. Mol Biol Cell 2004; 15: 4926-4937.
42. Papaleo F, Yang F, Garcia S, Chen J, Lu B, Crawley JN, et al. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol Psychiatry 2012; 17: 85-98.
43. Del Zompo M, Deleuze J-F, Chillotti C, Cousin E, Niehaus D, Ebstein RP, et al. Association study in three different populations between the GPR88 gene and major psychoses. Mol Genet Genom Med 2014; 2: 152-159.
44. Liu B, Xu H, Paton J, Kasparov S. Cell-and region-specific miR30-based gene knock-down with temporal control in the rat brain. BMC Mol Biol 2010; 11: 93.
45. Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006; 49: 603-615.
46. Snyder SH. Dopamine receptor excess and mouse madness. Neuron 2006; 49: 484-485.
47. Andreasen NC. Schizophrenia: the fundamental questions. Brain Res Brain Res Rev 2000; 31: 106-112.
48. Marenco S, Weinberger DR. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 2000; 12: 501-527.
49. Weinberger DR. On the plausibility of 'the neurodevelopmental hypothesis' of schizophrenia. Neuropsychopharmacology 1996; 14: 1S-11S.
50. Harich S, Gross G, Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 2007; 192: 511-519.
51. Wiley JL, Buhler KG, Lavecchia KL, Johnson KM. Pharmacological challenge reveals long-term effects of perinatal phencyclidine on delayed spatial alternation in rats. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 867-873.
52. Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008; 32: 1014-1023.
53. Jones CA, Watson DJ, Fone KC. Animal models of schizophrenia. Br J Pharmacol 2011; 164: 1162-1194.
54. Li J-X, Thorn DA, Jin C. The GPR88 receptor agonist 2-PCCA does not alter the behavioral effects of methamphetamine in rats. Eur J Pharmacol 2013; 698: 272-277.
55. O'Neill MF, Sanger GJ. A single pretreatment with MK-801 or cocaine enhances their locomotor stimulant effects in rats. Brain Res 1999; 834: 103-111.
56. Messier C, Mrabet O, Destrade C. Locomotor bias produced by intra-accumbens injection of dopamine agonists and antagonists. Pharmacol Biochem Behav 1992; 41: 177-182.
57. Pijnenburg AJ, Honig WM, Van Rossum JM. Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat. Psychopharmacologia 1975; 41: 87-95.
58. Voorn P, LJMJ Vanderschuren, Groenewegen HJ, Robbins TW, Pennartz CMA. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci 2004; 27: 468-474.
59. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001; 53: 119-134.
60. Freedman R. Schizophrenia. N Engl J Med 2003; 349: 1738-1749.
61. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67: 3-8.
62. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Therap 2010; 128: 419-432.
63. Engelmann M, Wotjak CT, Landgraf R. Social discrimination procedure: an alternative method to investigate juvenile recognition abilities in rats. Physiol Behav 1995; 58: 315-321.
64. Ferguson JN, Young LJ, Insel TR. The neuroendocrine basis of social recognition. Front Neuroendocrinol 2002; 23: 200-224.
65. Lu XC, Slotnick BM, Silberberg AM. Odor matching and odor memory in the rat. Physiol Behav 1993; 53: 795-804.
66. Gerlai R, Clayton NS. Analysing hippocampal function in transgenic mice: an ethological perspective. Trends Neurosci 1999; 22: 47-51.
67. Loiseau F, Millan MJ. Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D1 receptor agonists, but not of D2 antagonists. Eur Neuropsychopharmacol 2009; 19: 23-33.
68. Walaas SI, Hemmings HC, Greengard P, Nairn AC. Beyond the Dopamine receptor: regulation and roles of serine/threonine protein phosphatases. Front Neuroanat 2011; 5.
69. Southern C, Cook JM, Neetoo-Isseljee Z, Taylor DL, Kettleborough CA, Merritt A, et al. Screening ?-Arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen 2013; 18: 599-609.